Global Artificial Organs Market Research Report 2023-2028: From 3D Bioprinting to Neural Interfaces - New Technologies Paving the Way for Future Growth
25 août 2023 06h58 HE
|
Research and Markets
Dublin, Aug. 25, 2023 (GLOBE NEWSWIRE) -- The "Artificial Organs: Global Markets" report has been added to ResearchAndMarkets.com's offering. Global Artificial Organs Market is projected to reach...
Artificial Organ Global Market Report 2023: Sector to Reach $31 Billion by 2027 at an 8.7% CAGR
19 mai 2023 08h33 HE
|
Research and Markets
Dublin, May 19, 2023 (GLOBE NEWSWIRE) -- The "Artificial Organ Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global artificial organ market is expected...
Artificial Organs Global Market is Projected to Reach $38.9 Billion by 2030: Increasing Incidence of Cardiovascular Disease Drives the Market for Artificial Heart and VAD
24 avr. 2023 12h53 HE
|
Research and Markets
Dublin, April 24, 2023 (GLOBE NEWSWIRE) -- The "Artificial Organs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Artificial...
Diabetes Devices Market to Reach Over USD 90.2 Bn by 2031 with 6.0% of CAGR | TMR Study
17 avr. 2023 17h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, April 18, 2023 (GLOBE NEWSWIRE) -- The global diabetes devices market was valued at USD 50.5 Bn in 2021 and is anticipated to reach USD 90.2 Bn by 2031. ...
Artificial Organs Market to hit $30.9 billion by 2025: Global Market Insights, Inc.
07 nov. 2019 04h00 HE
|
Global Market Insights, Inc
Selbyville, Delaware, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Global Artificial Organs Market value is expected to cross USD 30.9 billion by 2025, according to a new research report by Global Market...
PharmaCyte Biotech Has Only Scratched the Surface With Its Cell-in-a-Box(R) Technology
17 août 2015 09h00 HE
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - August 17, 2015) - PharmaCyte Biotech Inc. (OTCQB: PMCB) has made a name for itself with the company’s potentially game-changing pancreatic cancer treatment, and also as the...
Xeris Pharmaceuticals Presents Non-Aqueous Glucagon Stability Data at the American Diabetes Association 73nd Scientific Sessions
21 juin 2013 10h00 HE
|
Xeris Pharmaceuticals, Inc.
Austin, TX, June 21, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris") announces today that it is
presenting at the American Diabetes Association 73nd Scientific
Sessions in Chicago, IL...
Xeris Pharmaceuticals Awarded Phase II Funding of NIH Fast -Track SBIR Grant to Advance Glucagon for the Artificial Pancreas
17 avr. 2013 11h39 HE
|
Xeris Pharmaceuticals, Inc.
Austin, TX, April 17, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based,
pharmaceutical company developing patient-friendly injectable
treatments for diabetes and other...
Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance Stable, Non-Aqueous Glucagon for Bi-Hormonal Artificial Pancreas
31 juil. 2012 10h41 HE
|
Xeris Pharmaceuticals, Inc.
Austin, TX, July 31, 2012 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, emerging
biopharmaceutical company developing patient-friendly injectable
treatments for diabetes...
PositiveID Corporation Finalizes First-in-Class Development of a Fully Synthetic Glucose Sensing System, a Critical Component of an Artificial Pancreas
05 mars 2012 08h00 HE
|
PositiveID Corporation
DELRAY BEACH, Fla., March 5, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID") (OTCBB:PSID), a developer of medical technologies for diabetes management, announced today that it has...